Physician profile
Jack Janani
NPI 1285047092
$1,481.10
in general payments reported to CMS, 2019-2025
14 companies · $387 in 2025
The $387 reported for 2025 was more than what 87% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $375 · 2021: $261 · 2022: $266 · 2023: $46.69 · 2024: $20.23 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $415 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $415.22 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.00 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $200.94 | 2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $152.41 | 2021-2022 | |
| Amgen INC. | $125.00 | 2022 | |
| Lilly USA, LLC | $125.00 | 2025 | Zepbound |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $124.82 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $118.06 | 2021 | |
| Sunovion Pharmaceuticals INC. | $113.64 | 2022 | |
| Merck Sharp & Dohme LLC | $46.69 | 2023 | Verquvo |
| Lundbeck LLC | $38.54 | 2025 | Rexulti |
| Novo Nordisk INC | $22.36 | 2025 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.23 | 2024 | Caplyta |
| Acadia Pharmaceuticals INC | $18.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Janani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.